naringenin has been researched along with Colorectal Cancer in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Abalo, R; Capasso, R; Entrialgo-Cadierno, R; Fernández, J; Lombó, F; Silván, B; Uranga, JA; Villar, CJ | 1 |
| Abdullah, S; Alhakamy, NA; Awan, ZA; Md, S | 1 |
| Chaurasia, S; Mishra, B; Patel, RR; Vure, P | 1 |
| Bode, AM; Chen, H; Cheng, KW; Dong, Z; Li, H; Lubet, RA; Oi, N; Wang, M; Zhu, F; Zykova, T | 1 |
| Cheng, KW; Fan, D; Hu, S; Li, ET; Ru, B; Wang, M; Zhang, J; Zhao, Y | 1 |
| Cho, SG; Choi, HY; Jeong, HS; Kang, GH; Kang, YJ; Kim, BW; Kim, HJ; Kim, JH; Lee, ER; Park, YS | 1 |
1 review(s) available for naringenin and Colorectal Cancer
| Article | Year |
|---|---|
Antiproliferative and palliative activity of flavonoids in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apigenin; Cell Proliferation; Colorectal Neoplasms; Drug Synergism; Flavanones; Flavonoids; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Luteolin; Palliative Care; Propiophenones | 2021 |
5 other study(ies) available for naringenin and Colorectal Cancer
| Article | Year |
|---|---|
Smart Oral pH-Responsive Dual Layer Nano-Hydrogel for Dissolution Enhancement and Targeted Delivery of Naringenin Using Protein-Polysaccharides Complexation Against Colorectal Cancer.
Topics: Colorectal Neoplasms; Delayed-Action Preparations; Flavanones; Humans; Hydrogels; Hydrogen-Ion Concentration; Nanoparticles; Particle Size; Polysaccharides; Solubility; Soybean Proteins; Spectroscopy, Fourier Transform Infrared; Water | 2022 |
Oral naringenin nanocarriers: Fabrication, optimization, pharmacokinetic and chemotherapeutic efficacy assessments.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Colon; Colorectal Neoplasms; Drug Carriers; Female; Flavanones; Humans; Male; Mice, Inbred BALB C; Nanoparticles; Particle Size; Polysaccharides; Rats, Wistar; Rectum | 2017 |
6-C-(E-phenylethenyl)-naringenin suppresses colorectal cancer growth by inhibiting cyclooxygenase-1.
Topics: Animals; Colorectal Neoplasms; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Disease Models, Animal; Female; Flavanones; HT29 Cells; Humans; Male; Mice; Mice, Nude; Transfection; Xenograft Model Antitumor Assays | 2014 |
6-C-(E-phenylethenyl)naringenin induces cell growth inhibition and cytoprotective autophagy in colon cancer cells.
Topics: Autophagy; Autophagy-Related Protein 7; Beclin-1; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Enzyme Inhibitors; Farnesol; Flavanones; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HCT116 Cells; HT29 Cells; Humans; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Molecular Docking Simulation; Necrosis; Phosphatidylinositol 3-Kinases; Protein Methyltransferases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; ras Proteins; Salicylates; TOR Serine-Threonine Kinases | 2016 |
Regulation of apoptosis by modified naringenin derivatives in human colorectal carcinoma RKO cells.
Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Flavanones; Flavonoids; Humans; Hydroxylation; Reactive Oxygen Species; Structure-Activity Relationship | 2008 |